Mounier Nicolas, Spina Michele, Gisselbrecht Christian
Groupe d'Etude des Lymphomes de l'Adulte, GELA, 1 av C Vellefaux, Paris, France.
Br J Haematol. 2007 Mar;136(5):685-98. doi: 10.1111/j.1365-2141.2006.06464.x. Epub 2006 Dec 1.
Patients infected with human immunodeficiency virus (HIV) are at greater risk of developing non-Hodgkin lymphoma than the general population and aggressive B-cell lymphoma has become one of the most common of the initial acquired immunodeficiency syndrome (AIDS)-defining illnesses. This review considers the prognostic factors and new approaches to the treatment of patients with AIDS-related lymphoma (ARL). As highly active antiretroviral therapy (HAART) became available, the survival of many ARL patients has become comparable to that of HIV-negative patients. This is partly due to the decrease in the incidence of opportunistic infections and improved prognosis. Both developments can also be attributed to new treatment strategies for ARL, such as the use of effective infusional regimens, Rituximab combinations and high-dose therapy with autologous stem-cell transplantation for relapsed disease. However, unresolved issues persist, such as the optimal therapy for patients with Burkitt ARL or central nervous system involvement.
感染人类免疫缺陷病毒（HIV）的患者患非霍奇金淋巴瘤的风险高于普通人群，侵袭性B细胞淋巴瘤已成为最初获得性免疫缺陷综合征（AIDS）定义疾病中最常见的疾病之一。本综述探讨了艾滋病相关淋巴瘤（ARL）患者的预后因素和新的治疗方法。随着高效抗逆转录病毒疗法（HAART）的出现，许多ARL患者的生存率已与HIV阴性患者相当。这部分归因于机会性感染发生率的降低和预后的改善。这两个进展也可归因于ARL的新治疗策略，如使用有效的输注方案、利妥昔单抗联合治疗以及对复发性疾病采用自体干细胞移植的高剂量治疗。然而，仍存在未解决的问题，如伯基特ARL或中枢神经系统受累患者的最佳治疗方法。
